P2.04-46 Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients by Jahan, N., Thein, K., Sultan, A., Swarup, S., Mogollon-Duffo, F., Adhikari, N., Arevalo, M., Htut, T., Naing, T., D’Cunha, N., Rehman, S., Hardwicke, F., Tijani, L.

Get full text

EP1.01-10 Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer by Jahan, N., Swarup, S., Sultan, A., Naing, T., Mogollon-Duffo, F., Ball, S., Tun, A., Htut, T., Dash, A., D’Cunha, N., Hardwicke, F., Awasthi, S., Tijani, L., Thein, K.

Get full text

MA03.07 First-Line Atezolizumab Chemoimmunotherapy in Advanced Non-Squamous NSCLC Patients Harboring EGFR/ALK Genetic Alterations by Thein, K., Jahan, N., Tun, A., Sultan, A., Swarup, S., Mogollon-Duffo, F., Yendala, R., Quirch, M., Htut, T., D’Cunha, N., Rehman, S., Hardwicke, F., Awasthi, S., Tijani, L.

Get full text

P2.04-86 Efficacy of Ipilimumab in Combination with Chemotherapy for First-Line Treatment of Advanced Lung Cancer by Htut, T., Tun, A., Swarup, S., Sultan, A., Mogollon-Duffo, F., Jahan, N., Adhikari, N., Oo, Y., Thida, A., Aung, H., Thi, W., Panigrahi, K., Tijani, L., Thein, K.

Get full text

Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer: EP1.01-10 by Jahan, N, Swarup, S, Sultan, A, Naing, T, Mogollon-Duffo, F, Ball, S, Tun, A, Htut, T, Dash, A, D’Cunha, N, Hardwicke, F, Awasthi, S, Tijani, L, Thein, K

Get full text